- Home
- GITS vs SXTP Comparison
GITS vs SXTP Comparison
Compare GITS & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | SXTP |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GITS | SXTP |
|---|---|---|
| Price | $2.75 | $3.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.60 |
| AVG Volume (30 Days) | 7.7M | ★ 10.5M |
| Earning Date | 11-12-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,867.00 | ★ $1,364,945.00 |
| Revenue This Year | N/A | $146.28 |
| Revenue Next Year | N/A | $24.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 202.10 |
| 52 Week Low | $0.66 | $1.36 |
| 52 Week High | $7.09 | $17.68 |
Technical Indicators
Market Signals| Indicator | GITS | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 59.46 |
| Support Level | $2.62 | $3.56 |
| Resistance Level | $4.65 | $4.44 |
| Average True Range (ATR) | 1.09 | 0.66 |
| MACD | -0.10 | -0.10 |
| Stochastic Oscillator | 16.16 | 28.57 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.